DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

Source link
#DB1310 #Duality #Biologics #Shanghai #NonSmall #Cell #Lung #Cancer #Likelihood #Approval